BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Enters into Agreements for $5M Registered Direct Offering

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering to total approximately $5 million; RVL Pharmaceuticals plans to use the funds for general corporate purposes. The registered direct offering agreements are for the purchase and sale of 11,870,846 of RVLP ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per share. According to the announcement, the company also agreed to issue unregistered series A-1 warrants to purchase up to 11,870,846 ordinary shares and unregistered series A-2 warrants to purchase up to 11,870,846 ordinary shares to the investors.

The announcement stated that the exercise price for the series A-1 warrants is $0.4212 per share; the warrants will be exercisable on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-1 warrants and will expire five years after the date of shareholder approval. The exercise prices for the series A-2 warrants is $0.4212 per share; those warrants will be exercisable on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-2 warrants and will expire 18 months after the date of shareholder approval.

To view the full press release, visit https://ibn.fm/Ner5u

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork